

Original investigation

Open Access

Brachial-ankle pulse wave velocity and symptomatic cerebral infarction in patients with type 2 diabetes: a cross-sectional study

Osamu Ogawa*, Tomio Onuma, Sayaka Kubo, Naomi Mitsuhashi, Chie Muramatsu and Ryuzo Kawamori

Address: Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo, 113-8421, Japan

Email: Osamu Ogawa* - GGD03273@nifty.ne.jp; Tomio Onuma - t-onuma@juntendo.gmc.ac.jp; Sayaka Kubo - skubo@td6.so-net.ne.jp; Naomi Mitsuhashi - n-mitsu@med.juntendo.ac.jp; Chie Muramatsu - chiechan@jcom.home.ne.jp; Ryuzo Kawamori - kawamori@med.juntendo.ac.jp

* Corresponding author

Published: 28 August 2003

Received: 23 June 2003

Cardiovascular Diabetology 2003, **2**:10

Accepted: 28 August 2003

This article is available from: <http://www.cardiab.com/content/2/1/10>

© 2003 Ogawa et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: Recently a new automatic device that measures brachial-ankle pulse wave velocity using an oscillometric method has been developed. However, the practical significance of brachial-ankle pulse wave velocity measurement remains uncertain. The purpose of this study was to examine the association between brachial-ankle pulse wave velocity and symptomatic cerebral infarction in patients with type 2 diabetes.

Methods: One thousand sixty six patients with type 2 diabetes were studied cross-sectionally. Measurements of brachial-ankle pulse wave velocity were made using the automatic device. Logistic regression analysis was used to calculate the odds ratio for cerebral infarction.

Results: The presence of symptomatic cerebral infarction was confirmed in 86 patients. In these patients brachial-ankle pulse wave velocity was found to be significantly higher than in patients without cerebral infarction (18.94 ± 4.95 versus 16.46 ± 3.62 m/s, $p < 0.01$). The association between brachial-ankle pulse wave velocity and cerebral infarction remained significant after adjustment for traditional risk factors. There was an increasing odds ratio for each tertile of brachial-ankle pulse wave velocity, from the second tertile (odds ratio, 2.28; 95% confidence interval, 1.05 to 4.94), to the third (odds ratio, 2.53; 95% confidence interval, 1.09 to 5.86).

Conclusion: Overall, we conclude that an increase in brachial-ankle pulse wave velocity is associated with symptomatic cerebral infarction in patients with type 2 diabetes.

Background

Pulse wave velocity (PWV) is the velocity of a pulse wave travelling a given distance between 2 sites in the arterial system. It has been reported that PWV gives an estimate of arterial stiffness, and an increase in aortic PWV has been associated with cardiovascular disease [1–4] Recently, a new, simple device to measure PWV has been developed.

The device measures brachial-ankle pulse wave velocity (baPWV) using an oscillometric method. [5] Unlike aortic PWV, baPWV includes measurements of peripheral artery velocity. Therefore, the clinical significance of baPWV may differ from that of aortic PWV. In order to assess the clinical significance of baPWV measurements, we investi-

Table 1: Characteristics of the 1066 patients enrolled in the study, divided according to the presence (+) or absence (-) of cerebral infarction.

	Cerebral infarction		p
	(+) n = 86	(-) n = 980	
baPWV(m/s)	18.94 ± 4.95	16.46 ± 3.62	<0.001
Age (years)	67.3 ± 7.8	60.3 ± 10.7	<0.001
Body mass index (kg/m ²)	23.9 ± 2.8	23.9 ± 3.8	0.89
Gender (male/female)	58/28	667/313	0.99
Duration of diabetes (years)	11.3 ± 9.1	9.4 ± 8.7	0.066
Antihypertensive agents (%)	43.0	33.4	0.44
Antihyperlipidemic agents (%)	30.2	22.5	0.14
Systolic blood pressure (mmHg)	137.0 ± 18.5	131.6 ± 19.6	0.014
Diastolic blood pressure (mmHg)	79.2 ± 10.6	78.8 ± 10.8	0.67
Hemoglobin A1c (%)	7.42 ± 1.5	7.56 ± 1.8	0.49
Total cholesterol (mmol/L)	4.95 ± 0.91	5.02 ± 1.06	0.86
HDL-cholesterol (mmol/L)	1.40 ± 0.44	1.47 ± 0.93	0.54
Triglycerides (mmol/L)	1.53 ± 0.83	1.72 ± 1.16	0.82
Smokers (%)	40.7	36.1	0.47

Plus-minus values are means ± S.D. baPWV: brachial ankle pulse wave velocity, HDL: high-density lipoprotein.

gated the association between baPWV and the presence of symptomatic cerebral infarction in patients with type 2 diabetes.


Methods

Patients with type 2 diabetes who underwent measurement of baPWV between April 2000 and November 2002 at the outpatient department of Juntendo University Hospital (Tokyo, Japan) were enrolled in this study. Informed consent was obtained from all subjects. Clinical data were collected cross-sectionally from the medical records. Type 2 diabetes was defined as a fasting plasma glucose concentration of more than 7.0 mmol/L when no treatment was given, or a plasma glucose concentration of 11.0 mmol/L or more 2 hours after a 75 g oral glucose load when being treated with glucose-lowering drugs. Patients selected had no history of ketoacidosis. Exclusion criteria were an ankle brachial pressure index (ABI) <0.9, a history of ischemic heart disease, and a history of atrial fibrillation. Symptomatic cerebral infarction was defined as a clinically apparent focal or global disturbance of cerebral function, and was diagnosed by neurological examination and cranial computer tomography or magnetic resonance imaging.

Total cholesterol, high-density lipoprotein cholesterol, triglycerides and hemoglobin A1c were determined using standard laboratory techniques. Weight and height were measured in the study subjects whilst they were wearing light clothing and no shoes. Body mass index (BMI) was calculated as weight (kilograms)/height (meters) squared.

baPWV, ABI and blood pressure (BP) were measured using an automatic waveform analyzer (BP-203RPE; Colin, Komaki, Japan). Measurements were taken with patients lying in a supine position after 5 minutes of rest in that position. Occlusion and monitoring cuffs were placed snugly around both sites of the upper and lower extremities of patients. Pressure waveforms of the brachial and tibial arteries were then recorded simultaneously by an oscillometric method.

Electrocardiogram monitoring was performed with electrodes placed on both wrists. Any arrhythmia recorded was evaluated. Heart sounds S1 and S2 were detected using a microphone placed on the left edge of the sternum at the fourth intercostal space. The pressure waveforms obtained at 2 different sites were simultaneously recorded to determine the time interval between the initial rise in the brachial and tibial pressure waveforms (T). The path length from the suprasternal notch to the elbow (L_a) and the path length from the suprasternal notch to the femur to the ankle (L_b) were automatically calculated based on the patient's height and were derived from statistical studies. baPWV was calculated using the formula $baPWV = (L_b - L_a)/T$. Measurement of right and left baPWV was obtained for an average of 10 seconds. The reproducibility of the baPWV measurements was high. In healthy subjects, the interobserver coefficient of variation (CV; n = 15) was 2.4% and the intraobserver CV (n = 17) was 5.8%. In patients with coronary heart disease, the interobserver CV (n = 18) was 8.4% and the intraobserver CV (n = 41) was 13.3%. [5] In 12517 subjects who had no medication and no history of cardiovascular disease, multiple regres-

**Figure 1**

Frequency distribution of brachial-ankle pulse wave velocity. Bar graph showing number of patients with a brachial-ankle pulse wave velocity (baPWV) in each range.

sion analysis demonstrated that age and blood pressure variables were potent, significant variables for baPWV. [6] The average of left and right baPWV was used for analysis. ABI was calculated using the formula $ABI = \text{ankle systolic BP} / \text{brachial systolic BP}$.

Statistical analysis

In order to assess the association between baPWV and cerebral infarction, we performed 2 statistical analyses. In the first, subjects were divided into 2 groups: those with and those without cerebral infarction. Clinical characteristics including baPWV were analyzed in the 2 groups. Continuous variables are given as mean \pm SD. We compared continuous variables using the Student's t-test. We compared

categorical data using the chi-squared test. A probability value <0.05 was considered statistically significant.

In the second form of analysis, multiple logistic regression analysis was used to provide an adjusted odds ratio for cerebral infarction. The variables included in the analysis were risk factors for cerebral infarction and factors influencing baPWV, including age, gender, BMI, duration of diabetes, smoking habit, systolic BP, and hyperlipidemia (defined as serum total cholesterol concentration >5.7 mmol/L, triglyceride concentration >1.7 mmol/L and/or treatment with antihyperlipidemic agents). The odds ratio is presented with 95% confidence intervals. Tertiles of the mean baPWV, age and systolic BP were used for logistic




Figure 2
Scattergram of age. Scattergram showing the ages of patients with and without cerebral infarction.

regression analyses. Statistical analyses were performed using StatView-J 5.0 computer software (SAS Institute Inc. Cary, NC, USA).

Results

Of 1066 patients eligible to take part in this study, the presence of symptomatic cerebral infarction was confirmed in 86 patients. Table 1 shows the characteristics of

the study group according to the presence or absence of cerebral infarction. baPWV, age, and systolic BP were significantly higher in patients with cerebral infarction than in those without. The frequency distribution of baPWV is shown in Figure 1. Scattergrams of age and baPWV in patients with and without cerebral infarction are shown in Figures 2 and 3, respectively.




Figure 3
Scattergram of brachial-ankle pulse wave velocity. Scattergram showing brachial-ankle pulse wave velocity (baPWV) in patients with and without cerebral infarction.

The adjusted odds ratios for cerebral infarction are shown in Table 2. The association between cerebral infarction and baPWV remained significant after adjustment for age, gender, diabetes duration, BMI, smoking habit, systolic BP, and hyperlipidemia. The odds ratios in the second and third tertiles for patient baPWV were significantly greater

than those in the lowest tertile. The odds ratios in the second and third tertiles for patient age were also significantly greater than those in the lowest tertile. Systolic BP, hyperlipidemia and duration were not significantly associated with cerebral infarction after adjustment.

Table 2: Adjusted odds ratios for cerebral infarction.

		No. of subjects	No. of events	Adjusted odds ratio (95% CI)	p
baPWV (m/s)	7.98–14.68	355	10	1.00	
	14.69–17.73	355	33	2.28 (1.05–4.94)	0.037
	17.74–39.57	356	43	2.53 (1.10–5.86)	0.030
Age (years)	23.2–56.9	358	10	1.00	
	57.0–66.4	363	28	2.52 (1.16–5.46)	0.019
	66.5–97.5	345	48	4.59 (2.10–10.06)	<0.001
Gender	female	341	28	1.00	
	male	725	58	1.04 (0.60–1.79)	0.90
Body mass index (per kg/m ²)				1.04 (0.97–1.12)	0.27
SBP (mmHg)	85–122	356	17	1.00	
	123–139	372	38	1.64 (0.87–3.10)	0.13
	140–219	338	31	1.22 (0.60–2.48)	0.59
Hyperlipidemia	no	461	36	1.00	
	yes	605	50	1.06 (0.66–1.70)	0.80
Duration of diabetes (per year)				1.00 (0.96–1.03)	0.99
Smokers	no	677	51	1.00	
	yes	389	35	1.60 (0.96–2.67)	0.074

baPWV: brachial ankle pulse wave velocity, CI: confidence interval, SBP: systolic blood pressure

Discussion

In this study, a high odds ratio for symptomatic cerebral infarction was associated with a high baPWV value, even after traditional risk factors for patients with type 2 diabetes had been taken into account. In a previous study, aortic PWV was shown to be associated with cerebrovascular disease. [1,7] In addition, there was a good correlation between aortic PWV and baPWV. [5] Our results support these findings.

Cerebral infarction is commonly considered to be either atherothrombotic, cardioembolic or lacunar. Cardioembolic infarction occurs together with arrhythmias, especially atrial fibrillation. [8] We excluded patients with atrial fibrillation; thus the cause of cerebral infarction in patients in this study would be expected to be atherothrombotic or lacunar in origin. Atherothrombotic infarction occurs together with atherosclerosis. Therefore, some patients with symptomatic cerebral infarction in this study would be expected to show atherosclerotic changes. In addition, as there was a good correlation between aortic PWV and baPWV, an increase in baPWV may reflect vascular damage. [5] Aortic PWV has been shown to be associated with atherosclerosis. [9,10] Therefore, baPWV is also associated with atherosclerosis.

An advantage of this non-invasive baPWV measurement method is that it is simple: only a set of cuffs for each limb is required and patients need not remove any clothing. Also, the reproducibility of the baPWV measurements taken was high. [5] Therefore, in clinical practice, measurement of baPWV may be a useful screening test for

atherosclerotic change. The degree of elevation of baPWV may correspond to the degree of atherosclerotic change: a very high baPWV may indicate that the atherosclerotic process is already well established.

The odds ratios of baPWV in second and third tertiles were similar, and did not increase linearly. This may have been due to an influence of blood pressure variables on baPWV [6] Additionally, the use of antihypertensive medication in patients with cerebral infarction may have decreased baPWV in this cross-sectional study.

As with any study there were limitations to the present investigation. For example, since this was a cross-sectional study, it is unclear from our results whether baPWV is a predictor for cerebral infarction. However, baPWV is strongly correlated with aortic PWV, [5] and aortic PWV is a recognised prognostic predictor [3,11,12] Therefore, it is possible that baPWV is also a useful predictor. A further limitation of the present study is that we have only studied patients with type 2 diabetes, so any associations in non-diabetic subjects remain to be investigated. In addition, since measurement of baPWV may be affected by peripheral conditions such as a lower ABI, caution is needed when interpreting these results. [13] A further prospective study of the general population would establish more clearly the clinical significance of baPWV measurement.

Conclusions

The present study showed that there is an association between symptomatic cerebral infarction and a high

baPWV value in patients with type 2 diabetes. baPWV may also be a useful marker of atherosclerosis.

Competing interests

Colin Corporation, Japan supported this study by supplying the pulse wave analyzer.

Authors' contributions

OO participated in the design of the study, performed statistical analyses and drafted the manuscript. TO contributed to the study design and revised the manuscript. SK carried out the measurements of pulse wave velocity and performed data collection. NM and CM carried out measurements of pulse wave velocity. RK participated in the study design and coordination.

References

1. Lehmann ED, Hopkins KD, Jones RL, Rudd AG and Gosling RG: **Aortic distensibility in patients with cerebrovascular disease.** *Clin Sci (Lond)* 1995, **89**:247-253.
2. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME and London GM: **Impact of aortic stiffness on survival in end-stage renal disease.** *Circulation* 1999, **99**:2434-2439.
3. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P and Benetos A: **Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients.** *Hypertension* 2001, **37**:1236-1241.
4. Meaume S, Benetos A, Henry OF, Rudnichi A and Safar ME: **Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age.** *Arterioscler Thromb Vasc Biol* 2001, **21**:2046-2050.
5. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S and Yamamoto Y: **Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement.** *Hypertens Res* 2002, **25**:359-364.
6. Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori T, Hori S, Yamamoto Y, Doba N and Hinohara S: **Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects.** *Atherosclerosis* 2003, **166**:303-309.
7. Nakano H, Okazaki K, Ajiro Y, Suzuki T and Oba K: **Clinical usefulness of measuring pulse wave velocity in predicting cerebrovascular disease: evaluation from a cross-sectional and longitudinal follow-up study.** *J Nippon Med Sch* 2001, **68**:490-497.
8. **Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III.** *Stroke* 1990, **21**:637-676.
9. van Popele NM, Grobbee DE, Bots ML, Asmar R, Topouchian J, Reneman RS, Hoeks AP, van der Kuip DA, Hofman A and Witteman JC: **Association between arterial stiffness and atherosclerosis: the Rotterdam Study.** *Stroke* 2001, **32**:454-460.
10. Taniwaki H, Kawagishi T, Emoto M, Shoji T, Kanda H, Maekawa K, Nishizawa Y and Morii H: **Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes.** *Diabetes Care* 1999, **22**:1851-1857.
11. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T and Nishizawa Y: **Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease.** *J Am Soc Nephrol* 2001, **12**:2117-2124.
12. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME and London GM: **Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.** *Circulation* 2001, **103**:987-992.
13. Lehmann ED, Riley WA, Clarkson P and Gosling RG: **Non-invasive assessment of cardiovascular disease in diabetes mellitus.** *Lancet* 1997, **350**:S114-9.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

